Current technologies: An introduction

EuroIntervention

Volumn 9, Issue , 2013, Pages R75-R82

  Daemen, Joost ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY DISSECTION; CAROTID SINUS PRESSORECEPTOR REFLEX; CATHETER COMPLICATION; DEVICE SAFETY; EUROPE; HUMAN; INFECTION RISK; KIDNEY ARTERY; KIDNEY DENERVATION; MEDICAL TECHNOLOGY; NERVE STIMULATION; PRODUCT PARAMETERS; RESISTANT HYPERTENSION; REVIEW; ADRENERGIC SYSTEM; ANIMAL; BLOOD PRESSURE; CATHETER ABLATION; CENTRAL VENOUS CATHETER; DRUG EFFECTS; DRUG RESISTANCE; EQUIPMENT DESIGN; HYPERTENSION; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; RENAL ARTERY; SYMPATHECTOMY; TREATMENT OUTCOME; VASCULARIZATION; ARTICLE; CONGENITAL MALFORMATION; DRUG EFFECT; EQUIPMENT; METHODOLOGY; PATHOLOGY; RADIOGRAPHY;

ANTIHYPERTENSIVE AGENT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATHETER ABLATION; DRUG RESISTANCE; EQUIPMENT DESIGN; HUMANS; HYPERTENSION; KIDNEY; RENAL ARTERY; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES;

EID: 84893351255     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9SRA13     Document Type: Review

References (20)

1. Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F, Bohm M, Dunlap M, Sadowski J, Bartus K, Kapelak B, Rocha-Singh KJ, Katholi RE, Witkowski A, Kadziela J, Januszewicz A, Prejbisz A, Walton AS, Sievert H, Id D, Wunderlich N, Whitbourn R, Rump LC, Vonend O, Saleh A,Thambar S, Nanra R, Zeller T, Erglis A, Sagic D, Boskovic S, Brachmann J, Schmidt M, Wenzel UO, Bart BA, Schmieder RE, Scheinert D, Börgel J, Straley C. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
2. Böhm M, Mahfoud F, Sievert H, Wunderlich N, Rump LC, Vonend O, Schmieder RE, Uder M, Lobo M, Caulfield M, Erglis A, Azizi M, Sapoval M, Thambar S, Persu A, Renkin J, Schunkert H, Weil J, Hoppe UC, Krum H, Walton T, Schlaich MP, Esler MD, Scheinert D, Binder T, Januszewicz A,Witkowski A, Ruilope LM, Whitbourn R, Bruck H, Downes M, Lüscher TF, Jardine AG, Webster MW, Zeller T, Sadowski J, Bartus K, Sobotka PA,Straley CA, Barman NC, Lee DP, Witteles RM, Bhalla V, Massaro JM. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9.
3. Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162:189-92.
4. Taborsky M. The effect of renal denervation in patients with advanced heart failure: The OLOMOUC I study. Presented at: European Society of Cardiology Congress 2012; August 27, 2012; Munich, Germany.
5. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-6.
6. Witkowski A, Prejbisz A, Florczak E, Kdziela J, ?liwiski P, Biele P, Michaowska I, Kabat M, Warcho E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
7. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-7.
8. Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, Böhm M, Lambert EA, Krum H, Sobotka PA, Schmieder RE, Ika-Sari C, Eikelis N, Straznicky N,Lambert GW, Esler MD. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with endstage renal disease. Int J Cardiol. 2013 [Epub ahead of print]
9. Ukena C, Mahfoud F, Spies A, Kindermann I, Linz D, Cremers B, Laufs U, Neuberger HR, Böhm M. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol. 2012 Aug 20. [Epub ahead of print]
10. Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR, Wirth K, Böhm M. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension. 2013;61:225-31.
11. Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T,de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254-8.
12. Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, Pertile T, Kieval R, Cody R. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44:1213-8.
13. Alnima T, Scheffers I, De Leeuw PW, Winkens B, Jongen-Vancraybex H, Tordoir JH, Schmidli J, Mohaupt MG, Allemann Y, Kroon AA. Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. J Hypertens. 2012;30:1665-70.
14. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA.Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-73.
15. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6:152-8.
16. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270-6.
17. Worthley S. EnligHTN I: Safety and efficacy of a novel multielectrode renal denervation catheter in patients with resistant hypertension: a first-in-man multi-center study. euroPCR 2012, Paris, France, May 16, 2012. http://www.pcronline.com/Lectures/2012/Safety-Andefficacy-of-A-novel-quadrapolar-renal-denervation-catheter-inpatients-with-resistant-hypertension-A-first-in-man-multicentre-study.
18. Papademetriou V. EnligHTN I: Safety and efficacy of a novel multi-electrode renal denervation catheter in patients with resistant hypertension: A First-in-Human Multicenter Study. Presented at AHA 2012 Congress, Los Angeles, USA, November 5, 2012.
19. Ormiston JA, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT, Webster MW. First-in-human use of the OneShot renal denervation system from Covidien. EuroIntervention. 2013;8:1090-4.
20. Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2012;8:57-61.